# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Yi Chen reiterates EyePoint Pharmaceuticals (NASDAQ:EYPT) with a Buy and maintains $30 price...
– Phase 3 trial design for the LUGANO and LUCIA pivotal non-inferiority trials of DURAVYU in wet AMD based on positive EOP2 mee...
Cantor Fitzgerald analyst Jennifer Kim reiterates EyePoint Pharmaceuticals (NASDAQ:EYPT) with a Overweight.
JP Morgan analyst Tessa Romero maintains EyePoint Pharmaceuticals (NASDAQ:EYPT) with a Overweight and lowers the price targe...
HC Wainwright & Co. analyst Yi Chen maintains EyePoint Pharmaceuticals (NASDAQ:EYPT) with a Buy and lowers the price tar...
Baird maintains EyePoint Pharmaceuticals (NASDAQ:EYPT) with a Outperform and lowers the price target from $46 to $38.